



Author index

Volume 238 (1995)

- Aarnoudse, J.G., see Kema, I.P. 238, 137
Agbedana, E.O., see Akanji, A.O. 238, 35
Akanji, A.O., E.O. Agbedana, Glycaemia and body mass as determinants of plasma lecithin: cholesterol acyltransferase activity in Nigerian patients with non-insulin dependent diabetes mellitus 238, 35
- Bando, S., see Saheki, S. 238, 43
Bertrand, M., see Boullier, A. 238, 1
Borguet, F., R. Cornelis, J. Delanghe, M.-C. Lambert, N. Lameire, Study of the chromium binding in plasma of patients on continuous ambulatory peritoneal dialysis 238, 71
Boullier, A., M. Hamon, E. Walters-Laporte, F. Martin-Nizart, R. Mackereel, J.-C. Fruchart, M. Bertrand, P. Duriez, Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease 238, 1
- Cant, A.J., see Montero, C. 238, 169
Cornelis, R., see Borguet, F. 238, 71
- Da Silva, V., S. Simonin, J.C. Deybach, H. Puy, Y. Nordmann, Variegated porphyria: diagnostic value of fluorometric scanning of plasma porphyrins 238, 163
Delanghe, J., see Borguet, F. 238, 71
Desmet, G., see Lemay, C. 238, 151
Deybach, J.C., see Da Silva, V. 238, 163
Duley, J.A., see Montero, C. 238, 169
Duriez, P., see Boullier, A. 238, 1
- Eriksson, T., B. Holmgren, Rapid degradation of 3,4-dihydroxyphenylalanine in plasma samples containing ethylenediaminetetraacetic acid 238, 209
- Fairbanks, L.D., see Montero, C. 238, 169
Falkous, G., J.B. Harris, D. Mantle, Effect of neurotoxic metal ions in vitro on proteolytic enzyme activities in human cerebral cortex 238, 125
Fruchart, J.-C., see Boullier, A. 238, 1
Fujimori-Arai, Y., see Hoshino, T. 238, 91
Fukao, T., see Watanabe, H. 238, 115
- Gidding, C.E.M., see Kema, I.P. 238, 137
Glueck, C.J., T. Tracy, L. Sieve-Smith, P. Wang, Whether, to what degree, and why lipoprotein(a) levels change over time 238, 11
Grabowski, G.A., see Lebwohl, M. 238, 101
- Hamon, M., see Boullier, A. 238, 1
Harris, J.B., see Falkous, G. 238, 125
Hayasaka, A., S. Iida, M. Ohto, Serum concentrations of the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen in chronic liver disease 238, 85
Hendry, B.M., see St. J. Dwight, J.F. 238, 187
Hitsumoto, Y., see Saheki, S. 238, 43
Hobbs, G.A., S.G. Wagner, S.S. Levinson, Relationships between triglycerides, lipoproteins, glucose and coronary artery disease 238, 59
Holmgren, B., see Eriksson, T. 238, 209
Hoshino, T., K. Kumasaka, K. Kawano, F. Yamagishi, I. Koyama, Y. Fujimori-Arai, T. Nakajima, T. Komoda, Low serum alkaline phosphatase activity associated with severe Wilson's disease. Is the breakdown of alkaline phosphatase molecules caused by reactive oxygen species? 238, 91

- Iida, S., see Hayasaka, A. 238, 85
- Karas, S.I., K.G. Yazykov, E.V. Makarova, Serotonin content in human blood platelets is not stable 238, 179
- Kawano, K., see Hoshino, T. 238, 91
- Kawasaki, S., M. Sano, F. Nagumo, J. Tadano, T. Maeda, Pedigree of a family with hyperalkaline-phosphatasemia apparently inherited as an autosomal recessive trait 238, 109
- Kema, I.P., C.J.F. Schoots, C.E.M. Gidding, A. Okken, J.G. Aarnoudse, F.A.J. Muskiet, *N*-Methyladrenaline: age-dependent urinary excretion, perinatal organ content and relation with 'classical' catecholamines 238, 137
- Komoda, T., see Hoshino, T. 238, 91
- Kondo, N., see Watanabe, H. 238, 115
- Konstadt, J., see Lebwohl, M. 238, 101
- Koreen, R., see Lebwohl, M. 238, 101
- Koyama, I., see Hoshino, T. 238, 91
- Kumasaka, K., see Hoshino, T. 238, 91
- Lambert, M.-C., see Borguet, F. 238, 71
- Lameire, N., see Borguet, F. 238, 71
- Lebwohl, M., M.O. Longas, J. Konstadt, R. Koreen, G.A. Grabowski, R. Phelps, G. Lemlich, E. Schwartz, Hyaluronic acid and dermatan sulfate in non-lesional pseudoxanthoma elasticum skin 238, 101
- Lemay, C., N. Roussel-Mizon, F. Thepot, G. Desmet, Maternal serum screening for fetal Down's syndrome, a retrospective study 238, 151
- Lemlich, G., see Lebwohl, M. 238, 101
- Levinson, S.S., see Hobbs, G.A. 238, 59
- Longas, M.O., see Lebwohl, M. 238, 101
- Mackereel, R., see Boullier, A. 238, 1
- Maeda, T., see Kawasaki, S. 238, 109
- Makarova, E.V., see Karas, S.I. 238, 179
- Mantle, D., see Falkous, G. 238, 125
- Martin-Nizart, F., see Boullier, A. 238, 1
- McBride, M.B., see Montero, C. 238, 169
- Micheli, V., see Montero, C. 238, 169
- Montero, C., J.A. Duley, L.D. Fairbanks, M.B. McBride, V. Micheli, A.J. Cant, G. Morgan, Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high performance liquid chromatography linked method 238, 169
- Morgan, G., see Montero, C. 238, 169
- Murase, M., see Saheki, S. 238, 43
- Muskiet, F.A.J., see Kema, I.P. 238, 137
- Nagumo, F., see Kawasaki, S. 238, 109
- Nakajima, T., see Hoshino, T. 238, 91
- Nordmann, Y., see Da Silva, V. 238, 163
- Ohto, M., see Hayasaka, A. 238, 85
- Okken, A., see Kema, I.P. 238, 137
- Orii, T., see Watanabe, H. 238, 115
- Paloheimo, L.I., J.F. Rehfeld, Quantitation of procholecystokinin and its products in plasma by processing-independent analysis 238, 21
- Phelps, R., see Lebwohl, M. 238, 101
- Puy, H., see Da Silva, V. 238, 163
- Rehfeld, J.F., see Paloheimo, L.I. 238, 21
- Roussel-Mizon, N., see Lemay, C. 238, 151
- Saheki, S., Y. Hitsumoto, S. Bando, M. Murase, N. Takeuchi, K. Uchida, Compositions of very low density lipoprotein subfractions from patients with polydisperse low density lipoproteins 238, 43
- Saiki, K., see Watanabe, H. 238, 115
- Sano, M., see Kawasaki, S. 238, 109
- Schoots, C.J.F., see Kema, I.P. 238, 137
- Schwartz, E., see Lebwohl, M. 238, 101
- Shimizu, N., see Watanabe, H. 238, 115
- Sieve-Smith, L., see Glueck, C.J. 238, 11
- Simonin, S., see Da Silva, V. 238, 163
- St. J. Dwight, J.F., B.M. Hendry, Actions of arachidonic acid on erythrocyte membrane Rb permeability 238, 187
- Tadano, J., see Kawasaki, S. 238, 109
- Takeuchi, N., see Saheki, S. 238, 43
- Thepot, F., see Lemay, C. 238, 151
- Tracy, T., see Glueck, C.J. 238, 11
- Uchida, K., see Saheki, S. 238, 43
- Wagner, S.G., see Hobbs, G.A. 238, 59
- Walters-Laporte, E., see Boullier, A. 238, 1
- Wang, P., see Glueck, C.J. 238, 11
- Watanabe, H., S. Yamaguchi, K. Saiki, N. Shimizu, T. Fukao, N. Kondo, T. Orii, Identification of the D-enantiomer of 2-hydroxyglutaric acid in glutaric aciduria type II 238, 115
- Wiener, K., Fasting plasma glucose as a diagnostic indicator of diabetes mellitus 238, 199
- Yamagishi, F., see Hoshino, T. 238, 91
- Yamaguchi, S., see Watanabe, H. 238, 115
- Yazykov, K.G., see Karas, S.I. 238, 179



Subject index

Volume 238 (1995)

- Adrenaline;** Phenylethanolamine-*N*-methyltransferase; Extra adrenal chromaffin tissue; High performance liquid chromatography **238, 137**
- Alkaline phosphatase activity;** Wilson's disease; Protein quantitation; Molecular sizes; Fragmentation; Reactive oxygen species **238, 91**
- Anti-ox-LDL autoantibodies;** LDL-immune complexes; Coronary artery disease **238, 1**
- Antioxidants;** Arachidonic acid; Erythrocyte; Membrane permeability; Lipid peroxidation **238, 187**
- Apoprotein;** VLDL subfraction; LDL heterogeneity; Lipoprotein composition; Gradient ultracentrifugation **238, 43**
- Arachidonic acid;** Antioxidants; Erythrocyte; Membrane permeability; Lipid peroxidation **238, 187**
- Atherogenicity;** ROC curves; Logistic regression; Lipoproteins; High density lipoprotein cholesterol; Triglycerides **238, 59**
- Atherosclerosis;** Diabetes; Non-insulin dependent obesity; Lecithin:cholesterol acyltransferase; High density lipoproteins **238, 35**
- Cholecystokinin;** Gene expression; Posttranslational processing; Processing-independent analysis; Radioimmunoassay; Trypsin cleavage **238, 21**
- Chromium;** Chromium binding; Plasma proteins; Continuous ambulatory peritoneal dialysis (CAPD) **238, 71**
- Chromium binding;** Chromium; Plasma proteins; Continuous ambulatory peritoneal dialysis (CAPD) **238, 71**
- Chronic liver disease;** Pyridinoline; Serum marker **238, 85**
- Coefficient of variation;** Lipoprotein(a); Coronary heart disease **238, 11**
- Continuous ambulatory peritoneal dialysis (CAPD);** Chromium; Chromium binding; Plasma proteins **238, 71**
- Coronary artery disease;** Anti-ox-LDL autoantibodies; LDL-immune complexes **238, 1**
- Coronary heart disease;** Lipoprotein(a); Coefficient of variation **238, 11**
- Dermatan sulfate;** Pseudoxanthoma elasticum; Hyaluronic acid **238, 101**
- Diabetes;** Non-insulin dependent obesity; Lecithin:cholesterol acyltransferase; High density lipoproteins; Atherosclerosis **238, 35**
- Diabetes mellitus;** Diagnostic criteria; Glucose tolerance test; Fasting plasma glucose; Screening; Predictive value **238, 199**
- Diagnostic criteria;** Diabetes mellitus; Glucose tolerance test; Fasting plasma glucose; Screening; Predictive value **238, 199**
- 3,4-Dihydroxyphenylalanine (DOPA) analysis;** Plasma; Ethylenediaminetetraacetic acid (EDTA); Heparin **238, 209**
- Down's syndrome screening;** Human chorionic gonadotropin; α -Fetoprotein; Unconjugated estriol; Risk factor **238, 151**
- Enantiomer;** 2-Hydroxyglutaric acid; Glutaric aciduria type II; Organic acidemia **238, 115**
- Erythrocyte;** Arachidonic acid; Antioxidants; Membrane permeability; Lipid peroxidation **238, 187**
- Erythrocytes;** Inosine monophosphate dehydrogenase; High performance liquid chromatography; Genetic purine disorders; Ribavirin **238, 169**
- Ethylenediaminetetraacetic acid (EDTA);** 3,4-

- Dihydroxyphenylalanine (DOPA) analysis; Plasma; Heparin 238, 209
- Extra adrenal chromaffin tissue**; Adrenaline; Phenylethanolamine-*N*-methyltransferase; High performance liquid chromatography 238, 137
- Fasting plasma glucose**; Diabetes mellitus; Diagnostic criteria; Glucose tolerance test; Screening; Predictive value 238, 199
- α -Fetoprotein**; Down's syndrome screening; Human chorionic gonadotropin; Unconjugated estriol; Risk factor 238, 151
- Fluorometric scanning**; Variegate porphyria; Protoporphyrinogen oxidase; Heme biosynthesis 238, 163
- Fragmentation**; Wilson's disease; Alkaline phosphatase activity; Protein quantitation; Molecular sizes; Reactive oxygen species 238, 91
- Gene expression**; Cholecystokinin; Posttranslational processing; Processing-independent analysis; Radioimmunoassay; Trypsin cleavage 238, 21
- Genetic purine disorders**; Inosine monophosphate dehydrogenase; Erythrocytes; High performance liquid chromatography; Ribavirin 238, 169
- Glucose tolerance test**; Diabetes mellitus; Diagnostic criteria; Fasting plasma glucose; Screening; Predictive value 238, 199
- Glutaric aciduria type II**; 2-Hydroxyglutaric acid; Organic acidemia; Enantiomer 238, 115
- Gradient ultracentrifugation**; VLDL subfraction; LDL heterogeneity; Lipoprotein composition; Apoprotein 238, 43
- Heme biosynthesis**; Variegate porphyria; Protoporphyrinogen oxidase; Fluorometric scanning 238, 163
- Heparin**; 3,4-Dihydroxyphenylalanine (DOPA) analysis; Plasma; Ethylenediaminetetraacetic acid (EDTA) 238, 209
- High density lipoprotein cholesterol**; ROC curves; Logistic regression; Lipoproteins; Triglycerides; Atherogenicity 238, 59
- High density lipoproteins**; Diabetes; Non-insulin dependent obesity; Lecithin:cholesterol acyltransferase; Atherosclerosis 238, 35
- High performance liquid chromatography**; Adrenaline; Phenylethanolamine-*N*-methyltransferase; Extra adrenal chromaffin tissue 238, 137
- High performance liquid chromatography**; Inosine monophosphate dehydrogenase; Erythrocytes; Genetic purine disorders; Ribavirin 238, 169
- Human blood platelets**; Serotonin content 238, 179
- Human brain**; Neurotoxicity; Neurodegeneration; Metal ions; Proteases 238, 125
- Human chorionic gonadotropin**; Down's syndrome screening; α -Fetoprotein; Unconjugated estriol; Risk factor 238, 151
- Hyaluronic acid**; Pseudoxanthoma elasticum; Dermatan sulfate 238, 101
- 2-Hydroxyglutaric acid**; Glutaric aciduria type II; Organic acidemia; Enantiomer 238, 115
- Inosine monophosphate dehydrogenase**; Erythrocytes; High performance liquid chromatography; Genetic purine disorders; Ribavirin 238, 169
- LDL heterogeneity**; VLDL subfraction; Lipoprotein composition; Apoprotein; Gradient ultracentrifugation 238, 43
- LDL-immune complexes**; Anti-ox-LDL autoantibodies; Coronary artery disease 238, 1
- Lecithin:cholesterol acyltransferase**; Diabetes; Non-insulin dependent obesity; High density lipoproteins; Atherosclerosis 238, 35
- Lipid peroxidation**; Arachidonic acid; Antioxidants; Erythrocyte; Membrane permeability 238, 187
- Lipoprotein composition**; VLDL subfraction; LDL heterogeneity; Apoprotein; Gradient ultracentrifugation 238, 43
- Lipoprotein(a)**; Coefficient of variation; Coronary heart disease 238, 11
- Lipoproteins**; ROC curves; Logistic regression; High density lipoprotein cholesterol; Triglycerides; Atherogenicity 238, 59
- Logistic regression**; ROC curves; Lipoproteins; High density lipoprotein cholesterol; Triglycerides; Atherogenicity 238, 59
- Membrane permeability**; Arachidonic acid; Antioxidants; Erythrocyte; Lipid peroxidation 238, 187
- Metal ions**; Human brain; Neurotoxicity; Neurodegeneration; Proteases 238, 125
- Molecular sizes**; Wilson's disease; Alkaline phosphatase activity; Protein quantitation; Fragmentation; Reactive oxygen species 238, 91
- Neurodegeneration**; Human brain; Neurotoxicity; Metal ions; Proteases 238, 125
- Neurotoxicity**; Human brain; Neurodegeneration; Metal ions; Proteases 238, 125

- Non-insulin dependent obesity;** Diabetes; Lecithin:cholesterol acyltransferase; High density lipoproteins; Atherosclerosis 238, 35
- Organic acidemia;** 2-Hydroxyglutaric acid; Glutaric aciduria type II; Enantiomer 238, 115
- Phenylethanolamine-*N*-methyltransferase;** Adrenaline; Extra adrenal chromaffin tissue; High performance liquid chromatography 238, 137
- Plasma;** 3,4-Dihydroxyphenylalanine (DOPA) analysis; Ethylenediaminetetraacetic acid (EDTA); Heparin 238, 209
- Plasma proteins;** Chromium; Chromium binding; Continuous ambulatory peritoneal dialysis (CAPD) 238, 71
- Posttranslational processing;** Cholecystokinin; Gene expression; Processing-independent analysis; Radioimmunoassay; Trypsin cleavage 238, 21
- Predictive value;** Diabetes mellitus; Diagnostic criteria; Glucose tolerance test; Fasting plasma glucose; Screening 238, 199
- Processing-independent analysis;** Cholecystokinin; Gene expression; Posttranslational processing; Radioimmunoassay; Trypsin cleavage 238, 21
- Proteases;** Human brain; Neurotoxicity; Neurodegeneration; Metal ions 238, 125
- Protein quantitation;** Wilson's disease; Alkaline phosphatase activity; Molecular sizes; Fragmentation; Reactive oxygen species 238, 91
- Protoporphyrinogen oxidase;** Variegate porphyria; Heme biosynthesis; Fluorometric scanning 238, 163
- Pseudoxanthoma elasticum;** Dermatan sulfate; Hyaluronic acid 238, 101
- Pyridinoline;** Serum marker; Chronic liver disease 238, 85
- Radioimmunoassay;** Cholecystokinin; Gene expression; Posttranslational processing; Processing-independent analysis; Trypsin cleavage 238, 21
- Reactive oxygen species;** Wilson's disease; Alkaline phosphatase activity; Protein quantitation; Molecular sizes; Fragmentation 238, 91
- Ribavirin;** Inosine monophosphate dehydrogenase; Erythrocytes; High performance liquid chromatography; Genetic purine disorders 238, 169
- Risk factor;** Down's syndrome screening; Human chorionic gonadotropin; α -Fetoprotein; Unconjugated estriol 238, 151
- ROC curves;** Logistic regression; Lipoproteins; High density lipoprotein cholesterol; Triglycerides; Atherogenicity 238, 59
- Screening;** Diabetes mellitus; Diagnostic criteria; Glucose tolerance test; Fasting plasma glucose; Predictive value 238, 199
- Serotonin content;** Human blood platelets 238, 179
- Serum marker;** Pyridinoline; Chronic liver disease 238, 85
- Triglycerides;** ROC curves; Logistic regression; Lipoproteins; High density lipoprotein cholesterol; Atherogenicity 238, 59
- Trypsin cleavage;** Cholecystokinin; Gene expression; Posttranslational processing; Processing-independent analysis; Radioimmunoassay 238, 21
- Unconjugated estriol;** Down's syndrome screening; Human chorionic gonadotropin; α -Fetoprotein; Risk factor 238, 151
- Variegate porphyria;** Protoporphyrinogen oxidase; Heme biosynthesis; Fluorometric scanning 238, 163
- VLDL subfraction;** LDL heterogeneity; Lipoprotein composition; Apoprotein; Gradient ultracentrifugation 238, 43
- Wilson's disease;** Alkaline phosphatase activity; Protein quantitation; Molecular sizes; Fragmentation; Reactive oxygen species 238, 91